OrbiMed-backed biotech quickly changes CEOs; Adaptimmune co-founder to lead Evaxionnews2025-10-31T11:00:30+00:00October 31st, 2025|Endpoints News|
Post-Hoc Live: Meet the scientists behind Baby KJ’s life-saving CRISPR therapynews2025-10-31T11:00:14+00:00October 31st, 2025|Endpoints News|
Vesper Bio reports early biomarker data for neurodegenerative disease candidatenews2025-10-31T10:57:21+00:00October 31st, 2025|Endpoints News|
Gilead sees cell therapy sales decline in Q3news2025-10-31T01:45:15+00:00October 31st, 2025|Endpoints News|
Novo’s Metsera offer could pose a test for Trump’s FTCnews2025-10-30T19:50:23+00:00October 30th, 2025|Endpoints News|
HHS approves 340B rebate model plans for Merck, Bristol Myers and othersnews2025-10-30T19:47:44+00:00October 30th, 2025|Endpoints News|
Lilly CEO expects more ‘noise’ as Metsera M&A fight beginsnews2025-10-30T19:32:53+00:00October 30th, 2025|Endpoints News|
Merck CEO touts Winrevair launch, says he’s looking for deals ‘with urgency’news2025-10-30T18:49:30+00:00October 30th, 2025|Endpoints News|
Post-Hoc Live: Breaking down the M&A drama between Pfizer, Metsera and Novonews2025-10-30T17:06:04+00:00October 30th, 2025|Endpoints News|
National Resilience secures $825M in funding; Regeneron details US manufacturing plansnews2025-10-30T15:34:59+00:00October 30th, 2025|Endpoints News|
